Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) – Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Ekso Bionics in a report issued on Tuesday, March 4th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.11) per share for the quarter, down from their prior estimate of ($0.06). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS and FY2028 earnings at $0.27 EPS.
Other equities research analysts also recently issued reports about the company. Lake Street Capital lowered their price target on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday. StockNews.com started coverage on Ekso Bionics in a report on Monday. They issued a “hold” rating for the company.
Ekso Bionics Stock Down 8.0 %
Shares of Ekso Bionics stock opened at $0.40 on Thursday. Ekso Bionics has a 1 year low of $0.37 and a 1 year high of $1.64. The business has a 50-day moving average of $0.61 and a two-hundred day moving average of $0.82. The company has a market capitalization of $8.86 million, a P/E ratio of -0.62 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $5.09 million during the quarter, compared to the consensus estimate of $5.05 million.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Featured Stories
- Five stocks we like better than Ekso Bionics
- How to Invest in Blue Chip Stocks
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- Where Do I Find 52-Week Highs and Lows?
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
